Immunitybio completes gmp drug substance manufacturing sufficient for 170,000 doses of anktiva®

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx) announced today that the drug substance (ds) has been completed and successfully qualified for “fill finish” (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg anktiva (nogapendekin alfa inbakicept-pmln). coupled with the recent announcement of a partnership with the serum institute of india (sii) for bcg availability, this provides the company with a significant initial supply of anktiva for com.
IBRX Ratings Summary
IBRX Quant Ranking